Format

Send to

Choose Destination
Cancer Res. 2009 Dec 15;69(24):9157-9. doi: 10.1158/0008-5472.CAN-09-2650.

Mutant metabolic enzymes are at the origin of gliomas.

Author information

1
The Pediatric Brain Tumor Foundation Institute, Duke University Medical Center, Durham, North Carolina, USA. hai.yan@duke.edu

Abstract

Mutations of the isocitrate dehydrogenase (IDH) metabolic enzymes IDH1 and IDH2 have been found to be frequent and early genetic alterations in astrocytomas and oligodendrogliomas. All mutations identified to date affect a single amino acid located within the isocitrate binding site (R132 of IDH1 and the analogous R172 residue of IDH2). IDH1 and IDH2 mutations define a specific subtype of gliomas and may have significant utility for the diagnosis, prognosis, and treatment of patients with these tumors.

PMID:
19996293
PMCID:
PMC2794981
DOI:
10.1158/0008-5472.CAN-09-2650
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for HighWire Icon for PubMed Central
Loading ...
Support Center